Search research articles
Contact Us
Filters
Showing results (71-80 of 168) with videos related to
Page
of 17
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
Giorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Cancers
|
December 10, 2021
Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium
Eva Obermayr, Elena Ioana Braicu, Stephan Polterauer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 15, 2020
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Antonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 1, 2016
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients
Iris J G Rutten, David P J van Dijk, Roy F P M Kruitwagen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2026
A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62)
Jalid Sehouli, Klaus Pietzner, Dario Zocholl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 24, 2012
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
Stephan Polterauer, Ignace Vergote, Nicole Concin, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 29, 2019
Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis
Melinda S Schuurman, Maite Timmermans, Toon van Gorp, et al.
Trials
|
February 19, 2013
Sentinel node in ovarian cancer: study protocol for a phase 1 study
Marjolein Kleppe, Toon Van Gorp, Brigitte F M Slangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles
Frank De Smet, Nathalie L M M Pochet, Bart L R De Moor, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
August 8, 2019
Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis
Jorne Ubachs, Janine Ziemons, Iris J G Minis-Rutten, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 168) with videos related to
Sort By:
Page
of 17
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
Giorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Cancers
|
December 10, 2021
Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium
Eva Obermayr, Elena Ioana Braicu, Stephan Polterauer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 15, 2020
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Antonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 1, 2016
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients
Iris J G Rutten, David P J van Dijk, Roy F P M Kruitwagen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2026
A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62)
Jalid Sehouli, Klaus Pietzner, Dario Zocholl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 24, 2012
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
Stephan Polterauer, Ignace Vergote, Nicole Concin, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 29, 2019
Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis
Melinda S Schuurman, Maite Timmermans, Toon van Gorp, et al.
Trials
|
February 19, 2013
Sentinel node in ovarian cancer: study protocol for a phase 1 study
Marjolein Kleppe, Toon Van Gorp, Brigitte F M Slangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles
Frank De Smet, Nathalie L M M Pochet, Bart L R De Moor, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
August 8, 2019
Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis
Jorne Ubachs, Janine Ziemons, Iris J G Minis-Rutten, et al.
Page
of 17